Gosuranemab
Based on 1 Customer Validation
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease.
For research use only. We do not sell to patients.
- Purity: 97.31%
- CAS No.: 1788032-39-2
- Molecular Weight:144.94 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG4 kappa
Human
Tau
Gosuranemab exhibits high binding affinity to monomeric and aggregated tau and removes seeding-competent tau from AD brain lysate[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized Fetal-tau/0N3R Protein, Human (His, solution, HY-P73618) can bind Gosuranemab. The EC50 for this effect is 3.367 ng/mL. -
Flow cytometric analysis of 1.5X106 SHSY5Y cells with Gosuranemab (HY-P99648, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa, Isotype Control (HY-P99003, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1788032-39-2
-
Appearance Liquid
-
Molecular Weight 144.94 kDa
-
Color Colorless to light yellow
-
SMILES
[Gosuranemab]
-
Synonyms
BMS-986168; IPN007; BIIB092
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Dam T, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451-1457. [Content Brief]
[2]. Shulman M, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease. Nat Aging. 2023;3(12):1591-1601. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)